Table 2.

Relationship between Non-overlapping primary molecular cytogenetic abnormalities and myeloma defining event at diagnosis in patients with immunoglobulin heavy chain (IgH) translocations.

FISH Abnormality	No. Of patiets	Bone Disease variant	Renal Failure variant	Anemia Variant	Mixed Variant
t(11;14), No. of patients (%)	86	30 (34.9%)	6 (7.0%)	12 (14.0%)	38 (44.2%)
t(4;14), No. of patients (%)	47	12 (25.5%)	3 (6.4%)	11 (23.4%)	21 (44.7%)
t(14;16), No. of patients (%)	24	3 (12.5%)	6 (25.0%)	4 (4.2%)	11 (45.8%)
t(14;20), No. of patients (%)	1	0 (0%)	0 (0%)	0 (0%)	1 (1.0%)
t(6;14), No. of patients (%)	3	1 (33.3%)	0 (0%)	1 (33.3%)	1 (33.3%)
Unknown Partner/Deletion of IgH Region, No. of patients (%)	59	22 (37.3%)	8 (13.6%)	5 (8.5%)	24 (40.7%)

^*Number and proportion represents the breakdown of patients with each cytogenetic subtype according to MDE